IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
28 May 2020
Pomezia, Italy - Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
7 February 2020
The Jenner Institute, Oxford University, UK and Advent Srl – an IRBM company, Pomezia,Italy - are continuing their long-standing history…